Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05743517 | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) | recruiting | N/A | 192 | Northwestern UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07368205 | Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging(PRSTEC_multipr) | recruiting | — | 350 | University Hospital Hradec KraloveOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07595224 | Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer(PostOP HYPOCxE) | recruiting | N/A | 120 | Siriraj HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05979610 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies(Reiki-Brachy) | recruiting | Phase 2 | 70 | University of UtahOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05049538 | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)(DOVE) | recruiting | Phase 2 | 198 | Yonsei UniversityOTHER | 7 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05687084 | Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial(MANEC) | recruiting | N/A | 1,030 | Universita di VeronaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | recruiting | Phase 3 | 254 | JW PharmaceuticalINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07558889 | The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population(ENDOCancerDATA) | recruiting | — | 10,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07173127 | The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters | recruiting | N/A | 30 | University Hospital, GenevaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555665 | REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification(REPLACE) | recruiting | — | 264 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06532539 | Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03785288 | Vaginal Cuff Brachytherapy Fractionation Study | recruiting | Phase 3 | 258 | Kara Romano, MDOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06268626 | Detection of Endometrial Cancer Through Risk Modelling(DETECTR) | recruiting | — | 1,000 | University of British ColumbiaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05559879 | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | recruiting | Phase 1 / Phase 2 | 37 | University of Alabama at BirminghamOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06751589 | A Study of a Weight Loss Intervention in People With Endometrial Cancer | recruiting | Early Phase 1 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07062016 | Molecular and ctDNA Characterization of High-Risk Endometrial Cancer | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06253494 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06547840 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha | recruiting | Phase 1 | 45 | Epsilogen LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer(EndoMAP) | recruiting | Phase 1 / Phase 2 | 148 | Alliance Foundation Trials, LLC.OTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07377734 | Intrauterine Injection of Type III Collage in FST of EC/AEH(2026ColECFerSp) | recruiting | Phase 2 | 30 | Wang JianliuOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05142033 | Avera Cancer Sequencing and Analytics Protocol (ASAP)(ASAP) | recruiting | — | 25,000 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06692335 | HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids | recruiting | N/A | 112 | Chinese University of Hong KongOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05112991 | Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | recruiting | Phase 2 | 108 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05990426 | Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy(FAST) | recruiting | N/A | 30 | Northwestern UniversityOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07480785 | TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients | recruiting | N/A | 780 | Zhejiang UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03968406 | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | recruiting | Phase 2 | 25 | Joyce Liu, MDOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07435623 | Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study | recruiting | — | 300 | Tata Memorial HospitalOTHER_GOV | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04997096 | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407959 | Screening and Staging of Benign vs Malignant Pelvic Abnormalities | recruiting | — | 60 | Mayo ClinicOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2026source: clinicaltrials